EGF and metastatic neoplasm: Although we do not understand the underlying mechanism, the lower toxicity in combination with better efficacy observed with bi‐EGF‐IT in vivo provides a better therapeutic window for its potential clinical development, not only for the treatment of primary tumors but also for recurrent and metastatic disease.